［1］董芬，张彪，单广良. 中国甲状腺癌的流行现状和影响因素［J］. 中国癌症杂志,2016,26(01):47-52.
DONG F,ZHANG B,SHAN GL. Distribution and risk factors of thyroid cancer in China［J］. China Oncology,2016,26(01):47-52.
［2］CHEN W,HE J,SUN K,et al. Cancer incidence and mortality in China,2014［J］. Chinese Journal of Cancer Research,2014,030(001):1-12.
［3］BALKWILL F,MANTOVANI A. Inflammation and cancer:Back to Virchow［J］. Lancet (London,England),2001,357(9255):539-545.
［4］FRENCH JD,BIBLE K,SPITZWEG C,et al. Leveraging the immune system to treat advanced thyroid cancers［J］. Lancet Diabetes Endocrinol,2017,5(6):469-481.
［5］GRIVENNIKOV SI,GRETEN FR,KARIN M.Immunity,inflammation,and cancer［J］. Cell,2010,140(6):0-899.
［6］HANAHAN D,WEINBERG RA. Hallmarks of cancer:The next generation［J］. Cell,2011,144(5):646-674.
［7］STOTZ M,PICHLER M,ABSENGER G,et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer［J］. Br J Cancer,2014,110(2):435-440.
［8］CHEN L,ZHANG F,SHENG XG,et al. Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1-IIa cervical cancer patients who undergo radical surgery［J］. Onco Targets Ther,2015,8:1355-1362.
［9］SYLMAN JL,MITRUGNO A,ATALLAH M,et al. The predictive value of inflammation-related peripheral blood measurements in cancer staging and prognosis［J］. Front Oncol,2018,8:78.
［10］SHI C,PAMER EG. Monocyte recruitment during infection and inflammation［J］. Nat Rev Immunol,2011,11(11):762-774.
［11］LIU Y,CAO X. The origin and function of tumor-associated macrophages［J］. Cell Mol Immunol,2015,12(1):1-4.
［12］CHANMEE T,ONTONG P,KONNO K,et al. Tumor-associated macrophages as major players in the tumor microenvironment［J］. Cancers (Basel),2014,6(3):1670-1690.
［13］FRIDLENDER ZG,SUN J,KIM S,et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta:"N1" versus "N2" TAN［J］. Cancer Cell,2009,16(3):183-194.
［14］DUMITRU CA,LANG S,BRANDAU S. Modulation of neutrophil granulocytes in the tumor microenvironment:mechanisms and consequences for tumor progression［J］. Semin Cancer Biol,2013,23(3):141-148.
［15］GONG W,YANG S,YANG X,et al. Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer［J］. Clinics (Sao Paulo),2016,71(6):311-314.
［16］张宗勤，张小峰，施乐华，等. 淋巴细胞浸润肿瘤的调节机制［J］. 中国肿瘤生物治疗杂志,2013,20(03):372-375.
ZHANG ZQ,ZHANG XF,SHI LH,et al. The regulation mechanisms of lymphocytes infiltrating into tumors［J］. Chinese Journal of Cancer Biotherapy,2013,20(03):371-375.
［17］GALDIERO MR,BONAVITA E,BARAJON I,et al. Tumor associated macrophages and neutrophils in cancer［J］. Immunobiology,2013,218(11):1402-1410.
［18］AGOSTON AT,SRIVASTAVA A,ZHENG Y,et al. Paraneoplastic thrombocytosis is associated with increased mortality and increased rate of lymph node metastasis in oesophageal adenocarcinoma［J］. Pathology,2017,49(5):471-475.
［19］REBECCA L STONE AMNI,EDWARD H AHN,VIRGINIA K BOND,et al. Paraneoplastic thrombocytosis in ovarian cancer［J］. The New England Journal of Medicine,2012,366(7):610-618.
［20］周文毓，陈金婵，惠宁. 治疗前血小板和淋巴细胞比值与宫颈癌新辅助化疗疗效及预后的相关性［J］. 中国肿瘤临床,2014,41(16):1045-1048.
ZHOU WY,CHEN JC,HUI N. Association of pre-treatment platelet-to-lymphocyte ratios with re-sponse to neoadjuvant chemotherapy and clinical outcomes of cer-vical cancer patients［J］. Chin J Clin Oncol,2014,41(16):1045-1048.
［21］YANG J,XU H,GUO X,et al. Pretreatment inflammatory indexes as prognostic predictors for survival in colorectal cancer patients receiving neoadjuvant chemoradiotherapy［J］. Sci Rep,2018,8(1):3044.
［22］GUO L,LIU S,ZHANG S,et al. C-reactive protein and risk of breast cancer:A systematic review and meta-analysis［J］. Sci Rep,2015,5:10508.
［23］LIU J,SHI Z,BAI Y,et al. Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer［J］. Cancer Manag Res,2019,11:4471-4480.
［24］KAWAI MHSOK. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer［J］. Surgery,2019,165(6):1151-1160.
［25］MI KS,HEUI KE,HYUN KB,et al. Association of the preoperative neutrophil-to-ymphocyte count ratio and platelet-to-lymphocyte count ratio with clinicopathological characteristics in patients with papillary thyroid cancer［J］. Endocrinology & Metabolism,2015,30(4):494-501.
［26］JIANG K,LEI J,LI C,et al. Comparison of the prognostic values of selected inflammation based scores in patients with medullary thyroid carcinoma:A pilot study［J］. J Surg Oncol,2017,116(3):281-287.
［27］OZMEN S,TIMUR O,CALIK I,et al. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer［J］. Endocr Regul,2017,51(3):131-136.
［28］KWAN HO LEE,EUN YOUNG SEOK,EUN YOUNG KIM,et al. Different prognostic values of individual hematologic parameters in papillary thyroid cancer due to age-related changes in immunity［J］. Annals of Surgical Treatment and Research,2019,96(2):70-77.
［29］SALIHA YILDIZ,ELIFE EKER,MINE OZTURK,et al. A comparison of haemogram parameters of patients with thyroid papillary cancer and nodular goiter in Van,Turkey［J］. Journal of Pakistan Medical Association,2019,69(11):1642-1646.
［30］赵跃，黄景昊，孙甲甲，等. 术前NLR、PLR、SII与甲状腺乳头状癌临床病理特征的关系［J］. 中华全科医学,2019,17(05):716-719.
ZHAO Y,HUANG JJ,SUN JJ,et al. Association of the preoperative NLR,PLR and SH with clinicopathological characteristics in patients with papillary thyroid cancer［J］. Chinese Journal of General Practice,2019,17(05):716-719.
［31］SERETIS C,GOURGIOTIS S,GEMENETZIS G,et al. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters:a pilot study［J］. Am J Surg,2013,205(6):691-696.
［32］KOCER D,KARAKUKCU C,KARAMAN H,et al. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders［J］. Asian Pacific Journal of Cancer Prevention Apjcp,2015,16(9):3875-3879.
［33］吴伟，张艳君，王冰，等. 术前外周血中性粒细胞与淋巴细胞计数比鉴别甲状腺良恶性结节临床价值研究［J］. 中国实用外科杂志,2016,36(02):227-229.
WU W,ZHANG YJ,WANG B,et al. Diagnostic value of preoperative peripheral blood neutrophil to lymphocyte ratio in identification of benign and malignant thyroid nodules［J］. Chinese Journal of Practical Surgery,2016,36(02):227-229.
［34］赵跃，郭永刚，孙甲甲，等. 术前SII、NLR、PLR在分化型甲状腺癌中的诊断价值分析［J］. 兰州大学学报(医学版),2018,44(06):50-56.
ZHAO Y,GUO YG,SUN JJ,et al. Diagnostic value of preoperative systemic immune-inflammation index,neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in differentiated thyroid carcinoma［J］. Journal of Lanzhou University (Medical Sciences),2018,44(06):50-56.
［35］SIT M,AKTAS G,ERKOL H,et al. Neutrophil to lymphocyte ratio is useful in differentiation of malignant and benign thyroid nodules［J］. P R Health Sci J,2019,38(1):60-63.
［36］CHO JS,PARK MH,RYU YJ,et al. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer［J］. Ann Surg Treat Res,2015,88(4):187-192.
［37］何时知，廉猛，翟杰，等. 侵袭性分化型甲状腺癌外周血中性粒细胞/淋巴细胞比值的临床意义［J］. 中国耳鼻咽喉头颈外科,2019,26(03):122-124.
HE SZ,LIAN M,ZHAI J,et al. Clinical significance of blood neutrophil-to-lymphocyte ratio in patients with invasive well-differentiated thyroid cancer［J］. Chinese Archives of Otolaryngology-Head and Neck Surgery,2019,26(03):122-124.
［38］LIU J,DU J,FAN J,et al. The neutrophil-to-lymphocyte ratio correlates with age in patients with papillary thyroid carcinoma［J］. ORL J Otorhinolaryngol Relat Spec,2015,77(2):109-116.
［39］林帅，高砚春. 术前外周血中性粒细胞/淋巴细胞比值对甲状腺癌预后的影响［J］. 临床肿瘤学杂志,2017,22(11):1017-1020.
LIN S,GAO YC. Effect of preoperative peripheral blood neutrophil to lymphocyte ratio on prognosis of thyroid cancer［J］. Chin Clin Oncol,2017,22(11):1017-1020.
［40］XU N,JIAN Y,WANG Y,et al. Evaluation of neutrophil-to-lymphocyte ratio and calcitonin concentration for predicting lymph node metastasis and distant metastasis in patients with medullary thyroid cancer［J］. Mol Clin Oncol,2018,9(6):629-634.
［41］LIU CL,LEE JJ,LIU TP,et al. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer［J］. J Surg Oncol,2013,107(5):493-497.
［42］孟泽，李培勇，严佶祺，等,乳头状甲状腺癌患者中性粒细胞和淋巴细胞比值与肿瘤特征的关系［J］. 安徽医药,2014,18(10):1880-1884.
MENG Z,LI PY,YAN JQ,et al. Blood neutrophil-to-lymphocyte ratio correlates with tumor prognosis in patients with papillary thyroid cancer［J］.Anhui Medical and Pharmacentical Journal,2014,18(10):1880-1884.
［43］KIM JY,PARK T,JEONG SH,et al. Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas［J］. Endocrine,2014,46(3):526-531.
［44］马恒，王晓雷. 术前中性粒细胞与淋巴细胞比值对甲状腺乳头状癌患者术后无复发生存的预测价值［J］. 山东医药,2015,55(16):15-17.
MA H,WANG XL. Predictive value of preoperative neutrophil-lymphocyte ratio on recurrence-free survival in patients with papillary thyroid carcinoma［J］.Shandong Medical Journal,2015,55(16):15-17.
［45］郑绪才，王圣应，刘建军，等. 中性粒细胞淋巴细胞比例在预测甲状腺乳头状癌术后侧颈部淋巴结复发的价值［J］. 河北医学,2017,23(09):1437-1440.
ZHENG XC,WANG SY,LIU JJ,et al. The value of neutrophil lymphocyte ratio in predicting recurrence of postoperative cervical lymph node metastatic in papillary thyroid carcinoma［J］.Hebei Medicine,2017,23(09):1437-1440.
［46］LEE F,YANG PS,CHIEN MN,et al. An increased neutrophil-to-lymphocyte patio predicts incomplete response to therapy in differentiated thyroid cancer［J］. Int J Med Sci,2018,15(14):1757-1763.
［47］宋杨梅. 甲状腺癌术前NLR及PLR与临床病理特征及预后分析［D］. 新疆:新疆医科大学,2015.
SONG YM. The relationship between preoperative NLR and PLR and clinicopathological characteristics in thyroid Cancer［D］.Xinjiang:Xinjiang Medical University,2015.
［48］LIU JF,BA L,LV H,et al. Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer:a meta-analysis［J］. Sci Rep,2016,6:38551.
［49］WEN W,WU P,LI J,et al. Predictive values of the selected inflammatory index in elderly patients with papillary thyroid cancer［J］. J Transl Med,2018,16(1):261.
［50］YOKOTA M,KATOH H,NISHIMIYA H,et al. Lymphocyte-monocyte ratio significantly predicts recurrence in papillary thyroid cancer［J］. J Surg Res,2020,246:535-543.
［51］SONG L,ZHU J,LI Z,et al. The prognostic value of the lymphocyte-to-monocyte ratio for high-risk papillary thyroid carcinoma［J］. Cancer Manag Res,2019,11:8451-8462.
［52］AHN J,SONG E,OH HS,et al. Low lymphocyte-to-monocyte ratios are associated with poor overall survival in anaplastic thyroid carcinoma patients［J］. Thyroid,2019,29(6):824-829.
［53］AHN J,SONG E,KIM WG,et al. Prognostic role of the lymphocyte-to-monocyte ratio for clinical outcomes of patients with progressive radioiodine-refractory differentiated thyroid carcinoma treated by sorafenib［J］. Clin Endocrinol (Oxf),2020,92(1):71-76.
［54］杨园园，单宏杰，郝中平. 炎症因子C反应蛋白在甲状腺乳头状癌患者血清中表达的临床意义［J］. 现代肿瘤医学,2019,27(09):1529-1531.
YANG YY,SHAN HJ,HAO ZP. The clinical significance of the expression of inflammatory factor C reactive protein in thyroid papillary carcinoma patients serum［J］.Modern Oncology,2019,27(9):1529-1531.
［55］STANCIU AE,SERDAREVIC N,HURDUC AE,et al. IL-4,IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto's thyroiditis［J］. Scand J Clin Lab Invest,2015,75(7):539-548.
［56］SHIMURA T,SHIBATA M,GONDA K,et al. Prognostic impact of elevated preoperative C-reactive protein on patients with differentiated thyroid carcinoma［J］. J Surg Res,2018,231:338-345.